CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company''s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Latest shares articles
Alibaba price forecast: Third-party price targets
Read our Alibaba price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:15, 30 April 2025
Amazon Q1 Preview: AI Ambitions Under Scrutiny Amid Trade Policy Headwinds and Margin Pressures
Amazon (AMZN) is set to report its Q1 2025 results after the close on May 1, with investors closely watching how the e-commerce and cloud giant is navigating a more challenging macroeconomic environment.
10:01, 30 April 2025
Apple Q2 Earnings Preview: US trade policy risks profit margins and China sales
Apple (AAPL) is scheduled to report its fiscal second-quarter (Q2 FY2025) results after the close on May 1, with investors weighing slowing demand trends against renewed geopolitical risks, notably the reemergence of US-China trade tensions.
14:33, 29 April 2025
Meta set to report Q1 earnings as ad-pricing headwinds test growth outlook
Meta Platforms (META) is scheduled to report its fiscal first-quarter earnings after the market closes on April 30. The social media giant heads into the results under pressure to maintain its growth trajectory amid emerging ad-pricing challenges and a softening macroeconomic environment.
09:22, 29 April 2025
Ratings and Reviews
Ratings and Reviews
